After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Yahoo Finance discussed the stock recently as it posted bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, BLUE falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.18 and fluctuated between $1.2000 as its day high and $1.0550 as its day low. The current market capitalization of Bluebird bio Inc is $227.43M. A total of 6.6 million shares were traded on the day, compared to an average of 12.89M shares.
Insider Activity
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, BLUE has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 5 SELLs from insiders. Insiders purchased 247,003 shares during that period but sold 25,131.
In the most recent transaction, Vittiglio Joseph sold 5,217 shares of BLUE for 0.90 per share on Feb 05. After the transaction, the Chief Business & Legal Officer now owns 44,783 company shares. In a previous transaction on Feb 05, Klima Thomas J sold 2,714 shares at 0.90 per share. BLUE shares that the insider owns now total 129,413.
Among the insiders who sold shares, Obenshain Andrew disposed of 1,879 shares on Feb 05 at a per-share price of $0.90. This resulted in the President and CEO holding 286,093 shares of BLUE after the transaction. In another insider transaction, Obenshain Andrew sold 3,162 shares at $1.43 per share on Jan 05. Company shares held by the President and CEO now total 287,972.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for BLUE in the last 3 months, the mean price target is $5.57 with high estimates of $13.00 and low estimates of $2.00. In terms of 52-week highs and lows, BLUE has a high of $5.53 and a low of $0.88.
As of this writing, BLUE has an earnings estimate of -$0.66 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.38 per share and a lower estimate of -$0.98. The company reported an EPS of -$0.67 in the last quarter, which was 6.90% higher than expectations of -$0.72.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BLUE’s latest balance sheet shows that the firm has $299.50M in Cash & Short Term Investments as of fiscal 2021. There were $89.58M in debt and $152.99M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $374.28M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BLUE is Buy with a score of 3.50.
